Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Enterprise Value (EV) 

Microsoft Excel

Current Enterprise Value (EV)

Abbott Laboratories, current enterprise value calculation

Microsoft Excel
Current share price (P) $91.13
No. shares of common stock outstanding 1,737,682,887
US$ in millions
Common equity (market value)1 158,355
Add: Preferred shares, one dollar par value, none issued (per books)
Add: Noncontrolling interests in subsidiaries (per books) 641
Total equity 158,996
Add: Current portion of long-term debt (per books) 3,033
Add: Long-term debt, excluding current portion (per books) 9,896
Total equity and debt 171,925
Less: Cash and cash equivalents 8,522
Less: Investments, primarily bank time deposits and U.S. treasury bills 417
Enterprise value (EV) 162,986

Based on: 10-K (reporting date: 2025-12-31).

1 Common equity (market value) = Share price × No. shares of common stock outstanding
= 91.13 × 1,737,682,887


Historical Enterprise Value (EV)

Abbott Laboratories, EV calculation

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Share price1, 2 $112.21 $134.92 $114.01 $106.74 $116.79
No. shares of common stock outstanding1 1,737,682,887 1,734,323,411 1,735,184,289 1,737,946,233 1,763,482,267
US$ in millions
Common equity (market value)3 194,985 233,995 197,828 185,508 205,957
Add: Preferred shares, one dollar par value, none issued (book value)
Add: Noncontrolling interests in subsidiaries (book value) 641 237 224 219 222
Total equity 195,626 234,232 198,052 185,727 206,179
Add: Current portion of long-term debt (book value) 3,033 1,500 1,080 2,251 754
Add: Long-term debt, excluding current portion (book value) 9,896 12,625 13,599 14,522 17,296
Total equity and debt 208,555 248,357 212,731 202,500 224,229
Less: Cash and cash equivalents 8,522 7,616 6,896 9,882 9,799
Less: Investments, primarily bank time deposits and U.S. treasury bills 417 351 383 288 450
Enterprise value (EV) 199,616 240,390 205,452 192,330 213,980

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Data adjusted for splits and stock dividends.

2 Closing price as at the filing date of Abbott Laboratories Annual Report.

3 2025 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 112.21 × 1,737,682,887


The information presents a five-year trend of several financial metrics, including common equity market value, total equity, total equity and debt, and enterprise value. Overall, enterprise value exhibits fluctuations mirroring changes in the underlying equity and debt components, with a general pattern of initial decline followed by growth and a subsequent decrease.

Enterprise Value Trend
Enterprise value decreased from US$213,980 million in 2021 to US$192,330 million in 2022, representing a decline of approximately 10.1%. It then increased to US$205,452 million in 2023, continued to grow to US$240,390 million in 2024, and subsequently decreased to US$199,616 million in 2025. This suggests potential volatility influenced by market conditions and company performance.
Equity Components
Common equity (market value) followed a similar pattern to enterprise value, decreasing from US$205,957 million in 2021 to US$185,508 million in 2022, increasing to US$197,828 million in 2023, peaking at US$233,995 million in 2024, and then declining to US$194,985 million in 2025. Total equity mirrored this trend, remaining closely aligned with the market value of common equity throughout the period.
Debt Influence
Total equity and debt increased from US$224,229 million in 2021 to US$248,357 million in 2024, before decreasing to US$208,555 million in 2025. The increase in total equity and debt between 2021 and 2024 contributed to the growth in enterprise value during that period. The subsequent decrease in total equity and debt in 2025 aligns with the decline in enterprise value observed in the same year.
Relationship between Metrics
Enterprise value consistently remains close to the sum of total equity and debt, indicating that debt plays a significant role in the company’s overall valuation. The fluctuations in enterprise value are largely explained by the combined changes in equity and debt levels.

The observed trends suggest a dynamic valuation influenced by both equity market performance and debt management. The decrease in enterprise value in the final year warrants further investigation to determine the underlying causes and potential implications.

AI Ask an analyst for more